In Zetia antitrust case, Merck and Glenmark ink deals with 2 plaintiff groups as retailers hold out

In February, a federal judge said Merck & Co. and Glenmark Pharmaceuticals would have to face a jury trial over an alleged pay-for-delay deal on the cholesterol med Zetia. Now, a pair of plaintiff groups has gotten in line behind settlement offers, but holdouts still could force the companies to defend themselves in court.